Clinical and Experimental Pediatrics

The Korean Pediatric Society (대한소아청소년과학회)
권호 표지
DOI QR코드

DOI QR Code

Haploidentical hematopoietic stem cell transplantation in children and adolescents with acquired severe aplastic anemia

  • Im, Ho Joon (Department of Pediatrics, Asan Medical Center Children’s Hospital, University of Ulsan College of Medicine) ;
  • Koh, Kyung-Nam (Department of Pediatrics, Asan Medical Center Children’s Hospital, University of Ulsan College of Medicine) ;
  • Seo, Jong Jin (Department of Pediatrics, Asan Medical Center Children’s Hospital, University of Ulsan College of Medicine)
  • Received : 2015.04.15
  • Accepted : 2015.04.20
  • Published : 2015.06.10
Download PDF
⟨ Previous Next ⟩

Abstract

Severe aplastic anemia (SAA) is a life-threatening disorder for which allogeneic hematopoietic stem cell transplantation (HSCT) is the current available curative treatment. HSCT from matched sibling donors (MSDs) is the preferred therapy for children with acquired SAA. For patients who lack MSDs, immunosuppressive therapy (IST) is widely accepted as a first-line treatment before considering HCT from an unrelated donor (URD). Given the recent progress in HSCT using URDs for childhood SAA, well-matched URDs became a realistic alternative for pediatric patients who have no suitable related donors and who are refractory to IST. However, it is quite challenging to treat patients with refractory SAA who lack suitable related or URDs. Even though haploidentical HSCT from genetically mismatched family members seemed to be an attractive procedure with the amazing benefit of readily available donors for most patients, early attempts were disappointing because of refractory graft-versus-host disease (GVHD) and excessively high transplant-related mortality. Recent advances with effective ex vivo depletion of T cells or unmanipulated in vivo regulation of T cells, better supportive care, and optimal conditioning regimens have significantly improved the outcome of haploidentical transplant. Besides considerable progress in the treatment of malignant diseases, recent emerging evidences for haploidentical HSCT in SAA has provided additional therapeutic options for patients with refractory diseases. Further improvements to decrease the rates of graft failure, GVHD, and infectious complications will facilitate the emergence of haploidentical HSCT as a front-line therapy for treating acquired SAA in children and adolescents who have no suitably matched donors.

Keywords

References

  1. Kikuchi A, Yabe H, Kato K, Koh K, Inagaki J, Sasahara Y, et al. Long-term outcome of childhood aplastic anemia patients who underwent allogeneic hematopoietic SCT from an HLA-matched sibling donor in Japan. Bone Marrow Transplant 2013;48:657-60. https://doi.org/10.1038/bmt.2012.205
  2. Schrezenmeier H, Passweg JR, Marsh JC, Bacigalupo A, Bredeson CN, Bullorsky E, et al. Worse outcome and more chronic GVHD with peripheral blood progenitor cells than bone marrow in HLA-matched sibling donor transplants for young patients with severe acquired aplastic anemia. Blood 2007;110:1397-400. https://doi.org/10.1182/blood-2007-03-081596
  3. Kim HK. Aplastic anemia. Korean J Pediatr 2007;50:519-23. https://doi.org/10.3345/kjp.2007.50.6.519
  4. Kojima S, Horibe K, Inaba J, Yoshimi A, Takahashi Y, Kudo K, et al. Long-term outcome of acquired aplastic anaemia in children: comparison between immunosuppressive therapy and bone marrow transplantation. Br J Haematol 2000;111:321-8. https://doi.org/10.1046/j.1365-2141.2000.02289.x
  5. Yoshida N, Kobayashi R, Yabe H, Kosaka Y, Yagasaki H, Watanabe K, et al. First-line treatment for severe aplastic anemia in children: bone marrow transplantation from a matched family donor versus immunosuppressive therapy. Haematologica 2014;99:1784-91. https://doi.org/10.3324/haematol.2014.109355
  6. Guinan EC. Acquired aplastic anemia in childhood. Hematol Oncol Clin North Am 2009;23:171-91. https://doi.org/10.1016/j.hoc.2009.01.011
  7. Young NS, Calado RT, Scheinberg P. Current concepts in the pathophysiology and treatment of aplastic anemia. Blood 2006;108: 2509-19. https://doi.org/10.1182/blood-2006-03-010777
  8. Bacigalupo A, Socie' G, Lanino E, Prete A, Locatelli F, Locasciulli A, et al. Fludarabine, cyclophosphamide, antithymocyte globulin, with or without low dose total body irradiation, for alternative donor transplants, in acquired severe aplastic anemia: a retrospective study from the EBMT-SAA Working Party. Haematologica 2010;95:976-82. https://doi.org/10.3324/haematol.2009.018267
  9. Kang HJ, Shin HY, Park JE, Chung NG, Cho B, Kim HK, et al. Successful engraftment with fludarabine, cyclophosphamide, and thymoglobulin conditioning regimen in unrelated transplantation for severe aplastic anemia: a phase II prospective multicenter study. Biol Blood Marrow Transplant 2010;16:1582-8. https://doi.org/10.1016/j.bbmt.2010.05.010
  10. Yagasaki H, Takahashi Y, Hama A, Kudo K, Nishio N, Muramatsu H, et al. Comparison of matched-sibling donor BMT and unrelated donor BMT in children and adolescent with acquired severe aplastic anemia. Bone Marrow Transplant 2010;45:1508-13. https://doi.org/10.1038/bmt.2009.378
  11. Scheinberg P, Nunez O, Weinstein B, Scheinberg P, Biancotto A, Wu CO, et al. Horse versus rabbit antithymocyte globulin in acquired aplastic anemia. N Engl J Med 2011;365:430-8. https://doi.org/10.1056/NEJMoa1103975
  12. Ades L, Mary JY, Robin M, Ferry C, Porcher R, Esperou H, et al. Long-term outcome after bone marrow transplantation for severe aplastic anemia. Blood 2004;103:2490-7. https://doi.org/10.1182/blood-2003-07-2546
  13. Kobayashi R, Yabe H, Hara J, Morimoto A, Tsuchida M, Mugishima H, et al. Preceding immunosuppressive therapy with antithymocyte globulin and ciclosporin increases the incidence of graft rejection in children with aplastic anaemia who underwent allogeneic bone marrow transplantation from HLA-identical siblings. Br J Haematol 2006;135:693-6. https://doi.org/10.1111/j.1365-2141.2006.06352.x
  14. Scheinberg P, Young NS. How I treat acquired aplastic anemia. Blood 2012;120:1185-96. https://doi.org/10.1182/blood-2011-12-274019
  15. Park JA, Koh KN, Choi ES, Jang S, Kwon SW, Park CJ, et al. Successful rescue of early graft failure in pediatric patients using T-cell-depleted haploidentical hematopoietic SCT. Bone Marrow Transplant 2014;49:270-5. https://doi.org/10.1038/bmt.2013.163
  16. Beatty PG, Clift RA, Mickelson EM, Nisperos BB, Flournoy N, Martin PJ, et al. Marrow transplantation from related donors other than HLA-identical siblings. N Engl J Med 1985;313:765-71. https://doi.org/10.1056/NEJM198509263131301
  17. Sykes M, Preffer F, McAfee S, Saidman SL, Weymouth D, Andrews DM, et al. Mixed lymphohaemopoietic chimerism and graft-versus-lymphoma effects after non-myeloablative therapy and HLA-mismatched bone-marrow transplantation. Lancet 1999; 353:1755-9. https://doi.org/10.1016/S0140-6736(98)11135-2
  18. Lang P, Schumm M, Greil J, Bader P, Klingebiel T, Muller I, et al. A comparison between three graft manipulation methods for haploidentical stem cell transplantation in pediatric patients: preliminary results of a pilot study. Klin Padiatr 2005;217:334-8. https://doi.org/10.1055/s-2005-872529
  19. Bethge WA, Faul C, Bornhauser M, Stuhler G, Beelen DW, Lang P, et al. Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: an update. Blood Cells Mol Dis 2008;40:13-9. https://doi.org/10.1016/j.bcmd.2007.07.001
  20. Handgretinger R, Chen X, Pfeiffer M, Mueller I, Feuchtinger T, Hale GA, et al. Feasibility and outcome of reduced-intensity conditioning in haploidentical transplantation. Ann N Y Acad Sci 2007;1106:279-89. https://doi.org/10.1196/annals.1392.022
  21. Daniele N, Scerpa MC, Caniglia M, Bernardo ME, Rossi C, Ciammetti C, et al. Transplantation in the onco-hematology field: focus on the manipulation of ${\alpha}$${\beta}$ and ${\gamma}$${\delta}$ T cells. Pathol Res Pract 2012;208:67-73. https://doi.org/10.1016/j.prp.2011.10.006
  22. Bertaina A, Merli P, Rutella S, Pagliara D, Bernardo ME, Masetti R, et al. HLA-haploidentical stem cell transplantation after removal of ${\alpha}{\beta}$+ T and B cells in children with nonmalignant disorders. Blood 2014;124:822-6. https://doi.org/10.1182/blood-2014-03-563817
  23. Huang XJ, Liu DH, Liu KY, Xu LP, Chen H, Han W, et al. Treatment of acute leukemia with unmanipulated HLA-mismatched/haploidentical blood and bone marrow transplantation. Biol Blood Marrow Transplant 2009;15:257-65. https://doi.org/10.1016/j.bbmt.2008.11.025
  24. Luznik L, O'Donnell PV, Symons HJ, Chen AR, Leffell MS, Zahurak M, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 2008;14:641-50. https://doi.org/10.1016/j.bbmt.2008.03.005
  25. Lang P, Teltschik HM, Feuchtinger T, Muller I, Pfeiffer M, Schumm M, et al. Transplantation of CD3/CD19 depleted allografts from haploidentical family donors in paediatric leukaemia. Br J Haematol 2014;165:688-98. https://doi.org/10.1111/bjh.12810
  26. Im HJ, Koh KN, Suh JK, Lee SW, Choi ES, Jang S, et al. Refinement of treatment strategies in ex vivo T-cell-depleted haploidentical SCT for pediatric patients. Bone Marrow Transplant 2015;50:225-31. https://doi.org/10.1038/bmt.2014.232
  27. Woodard P, Cunningham JM, Benaim E, Chen X, Hale G, Horwitz E, et al. Effective donor lymphohematopoietic reconstitution after haploidentical CD34+-selected hematopoietic stem cell transplantation in children with refractory severe aplastic anemia. Bone Marrow Transplant 2004;33:411-8. https://doi.org/10.1038/sj.bmt.1704358
  28. Lacerda JF, Martins C, Carmo JA, Lourenco F, Juncal C, Ismail S, et al. Haploidentical stem cell transplantation with purified CD34+ cells after a chemotherapy-alone conditioning regimen in heavily transfused severe aplastic anemia. Biol Blood Marrow Transplant 2005;11:399-400. https://doi.org/10.1016/j.bbmt.2005.02.007
  29. Passweg JR, Perez WS, Eapen M, Camitta BM, Gluckman E, Hinterberger W, et al. Bone marrow transplants from mismatched related and unrelated donors for severe aplastic anemia. Bone Marrow Transplant 2006;37:641-9. https://doi.org/10.1038/sj.bmt.1705299
  30. Koh KN, Im HJ, Kim BE, Choi ES, Jang S, Kwon SW, et al. Haploidentical haematopoietic stem cell transplantation using CD3 or CD3/CD19 depletion and conditioning with fludarabine, cyclophosphamide and antithymocyte globulin for acquired severe aplastic anaemia. Br J Haematol 2012;157:139-42. https://doi.org/10.1111/j.1365-2141.2011.08924.x
  31. Kremens B, Basu O, Grosse-Wilde H, Sauerwein W, Schaefer UW, Havers W. Transplantation of CD34-enriched peripheral stem cells from an HLA-haplotype mismatched donor to a patient with severe aplastic anemia. Bone Marrow Transplant 2001;27:111-3. https://doi.org/10.1038/sj.bmt.1702748
  32. Ciceri F, Lupo-Stanghellini MT, Korthof ET. Haploidentical transplantation in patients with acquired aplastic anemia. Bone Marrow Transplant 2013;48:183-5. https://doi.org/10.1038/bmt.2012.231
  33. Xu LP, Liu KY, Liu DH, Han W, Chen H, Chen YH, et al. A novel protocol for haploidentical hematopoietic SCT without in vitro T-cell depletion in the treatment of severe acquired aplastic anemia. Bone Marrow Transplant 2012;47:1507-12. https://doi.org/10.1038/bmt.2012.79
  34. Im HJ, Koh KN, Choi ES, Jang S, Kwon SW, Park CJ, et al. Excellent outcome of haploidentical hematopoietic stem cell transplantation in children and adolescents with acquired severe aplastic anemia. Biol Blood Marrow Transplant 2013;19:754-9. https://doi.org/10.1016/j.bbmt.2013.01.023
  35. Gao L, Li Y, Zhang Y, Chen X, Gao L, Zhang C, et al. Long-term outcome of HLA-haploidentical hematopoietic SCT without in vitro T-cell depletion for adult severe aplastic anemia after modified conditioning and supportive therapy. Bone Marrow Transplant 2014;49:519-24. https://doi.org/10.1038/bmt.2013.224
  36. Wang Z, Zheng X, Yan H, Li D, Wang H. Good outcome of haploidentical hematopoietic SCT as a salvage therapy in children and adolescents with acquired severe aplastic anemia. Bone Marrow Transplant 2014;49:1481-5. https://doi.org/10.1038/bmt.2014.187
  37. Clay J, Kulasekararaj AG, Potter V, Grimaldi F, McLornan D, Raj K, et al. Nonmyeloablative peripheral blood haploidentical stem cell transplantation for refractory severe aplastic anemia. Biol Blood Marrow Transplant 2014;20:1711-6. https://doi.org/10.1016/j.bbmt.2014.06.028
  38. Esteves I, Bonfim C, Pasquini R, Funke V, Pereira NF, Rocha V, et al. Haploidentical BMT and post-transplant Cy for severe aplastic anemia: a multicenter retrospective study. Bone Marrow Transplant 2015;50:685-9. https://doi.org/10.1038/bmt.2015.20
  39. Champlin RE, Horowitz MM, van Bekkum DW, Camitta BM, Elfenbein GE, Gale RP, et al. Graft failure following bone marrow transplantation for severe aplastic anemia: risk factors and treatment results. Blood 1989;73:606-13.
  40. Woodard P, Tong X, Richardson S, Srivastava DK, Horwitz EM, Benaim E, et al. Etiology and outcome of graft failure in pediatric hematopoietic stem cell transplant recipients. J Pediatr Hematol Oncol 2003;25:955-9. https://doi.org/10.1097/00043426-200312000-00010
  41. Lang P, Mueller I, Greil J, Bader P, Schumm M, Pfeiffer M, et al. Retransplantation with stem cells from mismatched related donors after graft rejection in pediatric patients. Blood Cells Mol Dis 2008; 40:33-9. https://doi.org/10.1016/j.bcmd.2007.06.027
  42. Feuchtinger T, Opherk K, Bethge WA, Topp MS, Schuster FR, Weissinger EM, et al. Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation. Blood 2010;116:4360-7. https://doi.org/10.1182/blood-2010-01-262089
  43. Oevermann L, Lang P, Feuchtinger T, Schumm M, Teltschik HM, Schlegel P, et al. Immune reconstitution and strategies for rebuilding the immune system after haploidentical stem cell transplantation. Ann N Y Acad Sci 2012;1266:161-70. https://doi.org/10.1111/j.1749-6632.2012.06606.x

Cited by

  1. Acquired aplastic anemia in Korean children: treatment guidelines from the Bone Marrow Failure Committee of the Korean Society of Pediatric Hematology Oncology vol.103, pp.4, 2015, https://doi.org/10.1007/s12185-016-1956-8
  2. Recent advances in haploidentical hematopoietic stem cell transplantation using ex vivo T cell-depleted graft in children and adolescents vol.51, pp.1, 2015, https://doi.org/10.5045/br.2016.51.1.8
  3. Haplo‐identical transplantation for acquired severe aplastic anaemia in a multicentre prospective study vol.175, pp.2, 2015, https://doi.org/10.1111/bjh.14225
  4. Improved outcome of haploidentical transplantation in severe aplastic anemia using reduced-intensity fludarabine-based conditioning vol.8, pp.48, 2015, https://doi.org/10.18632/oncotarget.19745
  5. Upfront haploidentical transplant for acquired severe aplastic anemia: registry-based comparison with matched related transplant vol.10, pp.1, 2015, https://doi.org/10.1186/s13045-017-0398-y
  6. Unmanipulated haploidentical transplantation conditioning with busulfan, cyclophosphamide and anti-thymoglobulin for adult severe aplastic anaemia vol.53, pp.2, 2015, https://doi.org/10.1038/bmt.2017.237
  7. Therapeutic Outcomes of Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Severe Aplastic Anemia: A Multicenter Study vol.102, pp.10, 2018, https://doi.org/10.1097/tp.0000000000002200
  8. Alternative donor transplants for severe aplastic anemia vol.2018, pp.1, 2015, https://doi.org/10.1182/asheducation-2018.1.467
  9. Donor-derived marrow mesenchymal stromal cell co-transplantation following a haploidentical hematopoietic stem cell transplantation trail to treat severe aplastic anemia in children vol.98, pp.2, 2015, https://doi.org/10.1007/s00277-018-3523-2
  10. Management of aplastic anemia after failure of frontline immunosuppression vol.12, pp.10, 2019, https://doi.org/10.1080/17474086.2019.1645003
  11. Haploidentical stem cell transplantation for aplastic anemia: the current advances and future challenges vol.56, pp.4, 2015, https://doi.org/10.1038/s41409-020-01169-7
  12. Selective T-cell depletion targeting CD45RA as a novel approach for HLA-mismatched hematopoietic stem cell transplantation in pediatric nonmalignant hematological diseases vol.114, pp.1, 2021, https://doi.org/10.1007/s12185-021-03138-2